IMI (International Medical Innovations) begins trial of early cancer markers
This article was originally published in Clinica
Canadian company International Medical Innovations (IMI) has begun trials of two new screening tests for early diagnosis of colorectal cancer, the third most common cancer in North America. It is the first large trial of the tests, known as CA1-18 and RMT, says Dr Norman Marcon, a gastroenterologist at St Michael's Hospital Toronto, where the 600-patient study is being carried out.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.